

Detailed Insight from Electronic Health-related Quality of Life Data in HIV for Payer Decision Making — A Way to Better Allocate Resources and Support Patients

ViiV Healthcare

PIN99

Evans TM¹, Cutts KN², Swinburn P³, Schmetz A³, Lykopoulos K⁴, Eitz Ferrer P⁵

¹ViiV Healthcare, Research Triangle Park, NC, USA; ²Evidera, Bethesda, MD, USA; ³Evidera, London, UK; ⁴Independent Researcher, London, UK; ⁵Independent Researcher, Raleigh, NC, USA

Introduction

- There has been an increased interest in the applications of realworld data (RWD) in drug development.
- Many organizations now have or are in the process of building RWD analytical capabilities. Patient registries, healthcare databases and pharmacy/ insurance databases have been used as sources of data.
- The life expectancy of people living with HIV (PLHIV) in the United States (US) has improved dramatically in the last 25 years and more than ever are virally suppressed (VS). However, HIV is a complex chronic condition associated with myriad concurrent conditions.
- A novel approach to collecting RWD was utilized to understand the unmet needs and health-related quality of life (HRQoL) of PLHIV.

Objectives

- This study aimed to:
 - Evaluate HRQoL and treatment satisfaction in PLHIV who have achieved viral suppression.
 - Explore the potential of novel data collected through electronic administration of a survey via mobile app to inform payer decision-making.

Methods

Study Design

- The “Real-world Insights of patients living with HIV (PLHIV) Shared through Electronic devices” (RISE) study was a cross-sectional survey to obtain a current understanding of the impact HIV has on patients’ lives in the US.

Patient Population

- Patients were eligible to participate if they were at least 21 years old, read and understood English or Spanish, diagnosed with HIV, and had a smartphone with access to internet.
- PLHIV were recruited through several social media platforms and completed the survey on a mobile app downloaded directly to their device.


Measures

- The survey included a sociodemographic and clinical section, and seven validated patient-reported outcome (PRO) measures. Results from the Functional Assessment of HIV Infection (FAHI), Patient Satisfaction Questionnaire (PSQ-18), Patient Health Questionnaire (PHQ-2), and medication adherence visual analog scale (VAS) were presented to three US payers from Medicaid and commercial plans. Figure 1 shows an example screenshot from the RISE mobile app.

Statistical Analyses

- Study measures were summarized using descriptive statistics. Frequencies and percentages were reported for categorical variables; means, medians, and standard errors for continuous variables. In addition, differences in respective scores were evaluated using analysis of variance (ANOVA).

Figure 1. Example Screenshot of RISE Mobile App



Results

Demographics

- Of the 11,687 PLHIV who passed screening, only 2,648 consented to participate in RISE. Completion rates for the measures ranged from 46.3%–44.7%.
- Overall, 1,226 completed the RISE study, with 1,134 patients being virally suppressed. A majority of the sample (n=695; 56.7%) completed the survey on an Android device. Virally suppressed participant demographics are presented in Table 1.
- The majority reported taking a single treatment regimen (63.2%) and were very satisfied with their treatment (76.3%). Most patients reported visiting their HIV provider every three (48.9%) or six (41.8%) months.
- Patients averaged 3.8 comorbidities, with most reporting experiencing anxiety (84.1%), other sexual transmitted infections (50.4%), and depression (47.0%).

HRQoL by Insurance Groups

- Table 2 shows the results of the FAHI score by insurance group. All mean FAHI scores were larger on average for private health insurance; however, the key drivers of this increased HRQoL were the physical and functional/global well-being scores.
- Medicaid patients showed a higher tendency for depression compared with other insurance groups with a score of 2.3 on the PHQ-2 (p<0.005).
- Patients with private health insurance reported higher general satisfaction (p=0.01), technical quality (p=0.04), and accessibility and convenience score (p=0.003) compared with other insurance groups; Medicaid patients reported higher satisfaction with financial aspects (p<0.005).
- Patients on private health insurance also reported higher adherence rates (mean=95.5) relative to patients on Medicaid, who reported the lowest adherence (mean=88.5) (p<0.005).

Results (cont’d)

Table 1. Virally Suppressed Patient Demographic Characteristics

Sociodemographic Characteristics	Virally-suppressed (n=1,134)	Sociodemographic Characteristics	Virally-suppressed (n=1,134)
Gender		Type of Health Insurance	
Male	933 (82.3%)	Private Health Insurance	486 (42.9%)
Female	184 (16.2%)	Ryan White	134 (11.8%)
Transgender – Male to Female	10 (0.9%)	Medicare	256 (22.6%)
Transgender – Female to Male	3 (0.3%)	Medicaid	191 (16.8%)
Other	4 (0.4%)	Military Healthcare (Tricare/VA)	19 (1.7%)
Sexual Orientation		Other Government Program	33 (2.9%)
Heterosexual/Straight	188 (16.6%)	No Coverage of Any Type	8 (0.7%)
Homosexual/Gay/Lesbian	883 (77.9%)	Don’t Know	7 (0.6%)
Bisexual	53 (4.7%)	US Region	
Asexual	3 (0.3%)	Northeast	193 (17.0%)
Other	6 (0.5%)	Midwest	176 (15.5%)
Prefer Not to Say	1 (0.1%)	South	497 (43.8%)
Age		West	268 (23.6%)
Less than 50 Years Old	641 (56.5%)	Ethnicity/Race	
≥50 Years Old	489 (43.1%)	Black, Non-Hispanic	286 (25.2%)
Missing	4 (0.4%)	White, Non-Hispanic	617 (54.4%)
Abbreviations: US, United States; VA, Veteran’s Affairs		Hispanic or Latino	181 (16.0%)
		Other	50 (4.4%)

Table 2. FAHI Scores by Insurance Group

FAHI Score	Insurance (N=1,051)				p-value ¹	Effect Size ²
	Private Health Insurance (n=480)	Ryan White (n=129)	Medicare (n=254)	Medicaid (n=188)		
Total Score						
Mean (SE)	122.0 (1.41)	110.5 (2.73)	105.4 (1.94)	104.1 (2.26)	<0.0001	ES12=0.37 ES32=0.16 ES42=0.19
Median (Q1, Q3)	126.0 (101, 145)	111.0 (87, 140)	106.1 (85, 128)	101.5 (81, 131)		
Physical Well-being Score						
Mean (SE)	31.84 (0.37)	28.80 (0.71)	25.88 (0.51)	26.24 (0.59)	<0.0001	ES12=0.41 ES32=0.34 ES42=0.29
Median (Q1, Q3)	34.0 (28, 37)	30.0 (23, 36)	26.5 (20, 33)	27.0 (20, 34)		
Emotional Well-being Score						
Mean (SE)	26.83 (0.42)	24.85 (0.80)	26.18 (0.57)	24.51 (0.67)	0.0113	ES12=0.22 ES32=0.14 ES42=0.04
Median (Q1, Q3)	28.5 (22, 33)	26.0 (17, 34)	27.0 (19, 34)	25.5 (18, 32)		
Functional and Global Well-being Score						
Mean (SE)	36.20 (0.47)	32.05 (0.90)	28.40 (0.64)	29.56 (0.75)	<0.0001	ES12=0.42 ES32=0.35 ES42=0.22
Median (Q1, Q3)	38.0 (30, 44)	32.0 (25, 41)	27.0 (21, 36)	28.0 (22, 37)		
Social Well-being Score						
Mean (SE)	18.99 (0.36)	17.51 (0.69)	17.75 (0.49)	17.06 (0.58)	0.0148	ES12=0.19 ES32=0.03 ES42=0.05
Median (Q1, Q3)	19.0 (13, 25)	18.0 (10, 24)	18.0 (12, 24)	17.0 (10, 24)		
Cognitive Functioning Score						
Mean (SE)	8.11 (0.13)	7.29 (0.26)	7.19 (0.18)	6.76 (0.21)	<0.0001	ES12=0.28 ES32=0.03 ES42=0.17
Median (Q1, Q3)	8.0 (6, 10)	7.0 (5, 10)	7.0 (5, 9)	7.0 (5, 9)		

Abbreviations: FAHI, Functional Assessment of HIV Infection; SE, standard error

US Payer Interviews

- Payers acknowledged there was still unmet needs in HIV due to the increased longevity of PLHIV. These included living with comorbidities, adherence and compliance, and extended quality of life.
- Payers agreed that RWD studies provide an opportunity to capture the patient’s voice but would be more valuable if they were developed with the goal of providing actionable items (i.e., roadmaps to improving patient care).
 - A way to enhance RWD studies is to include payer stakeholders at the study design and initial development stage.
- Overall, the payers found the RISE results interesting but suggested the

following:

- Dive deeper into the healthcare system and generate actionable ways to improve care
- Provide longitudinal follow-up with RISE patients to assess long-term changes in treatment care
- Include case-control comparisons with US general population
- Physicians and case managers may benefit the most from studies such as RISE to help target ways to improve HRQoL within specific groups of interest.

Limitations

- A number of limitations were identified—these pertained largely to the recruitment and data collection methods employed in the study. Participants were recruited via social media and were required to complete the survey via a mobile app, which may have contributed to the sociodemographic bias observed in the sample. There was evidence of reduced ethnic diversity in the study population with under-representation of Black and Hispanic individuals when compared with the US HIV population data (Center for Disease Control and Prevention 2016).
- In addition, there was a substantial survey non-completion rate (22.7%), such that potential participants completed eligibility questions, but did not complete informed consent. Only 46.3% of participants who consented downloaded the app and completed at least the sociodemographic and medical information section.

References

- Centers for Disease Control and Prevention (CDC). HIV Surveillance Report, 2016; vol. 28. <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published November 2017. Accessed 19 November 2018.
- Hill A, Roberts J, Ewings P, Gunnell D. Non-response bias in a lifestyle survey. Journal of Public Health. 1997;19(2):203-207.

Conclusions

- Payers believe that RWD offers enormous potential for decision-making, especially in resource allocation or policy and formulary design.
- HIV patients still have unmet needs related to HRQoL that require consideration from a variety of stakeholders, including education and access to treatment to improve adherence.
- Electronic mobile patient surveys can be beneficial to inform decision-making in a wide range of diseases, including diabetes, asthma, and oncology.